Investigating molecular markers in the development of Lymphangioleiomyomatosis (LAM)
Official title: Molecular Biomarkers in pathogenesis of Lymphangioleiomyomatosis (LAM)
Funded at Columbia University Health Sciences · NIH-10924017 · Data updated 2026-11-12
This study is looking at how a specific pathway in the body might influence the progression of Lymphangioleiomyomatosis (LAM) and how it could help doctors find better ways to diagnose and treat this lung disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 10, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $695,144 |
| NIH project number | 5R01HL167137-02 |
| Project ID | NIH-10924017 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Lymphangioleiomyomatosis (LAM), particularly those who have not responded well to current treatments.
✕Less likely to help
Patients with LAM who are already receiving effective treatment or those with other unrelated respiratory conditions may not benefit from this research.
What this research studies
This research focuses on Lymphangioleiomyomatosis (LAM), a serious lung disease that can lead to respiratory failure. The study aims to understand the role of the HMGA2 signaling pathway in the disease's progression and how it may affect treatment responses. By examining the expression of HMGA2 and related genes, researchers hope to identify biomarkers that can help diagnose and assess the severity of LAM. The approach includes both genetic and pharmacological methods to explore the potential for improved treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostic tools and targeted therapies for patients with LAM.
How similar studies have gone: Previous studies have shown promise in exploring molecular pathways in LAM, but this specific approach focusing on HMGA2 is relatively novel.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: D'armiento, Jeanine M — Columbia University Health Sciences
- Study coordinator: D'armiento, Jeanine M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.